Ocaliva® (obeticholic acid) – Safety update
May 26, 2021 - The FDA announced that a new Contraindication will be added to the Ocaliva (obeticholic acid) drug label stating that it should not be used in primary biliary cholangitis (PBC) patients with advanced cirrhosis.
Download PDF
